Lip-Bu Tan, Chairman, Walden International and Founding Managing Partner, Walden Catalyst Ventures, has joined the advisory board of 4baseCare, an Illumina Accelerator company that offers precision oncology solutions using advanced genomics and digital health technology.
Lip-Bu Tan has over 30 years of experience in deep tech venture capital. Furthermore, Lip-Bu Tan is the anchor investor and advisor at Yali Capital, a homegrown deep-tech venture fund that recently led 4baseCare’s $ 6 million Series A funding round.
He serves on the Health Executive Council at the University of California, San Francisco (UCSF). Additionally, he is the Chairman of Greenstone Biosciences, a company pioneering the transformation of drug discovery, and a Chairman of Artera, a company offering AI-enabled predictive and prognostic cancer tests.
Commenting on his appointment, Lip-Bu Tan, said, “4baseCare’s test meets a very large unmet need in the Asian and Middle Eastern markets where treatment decisions for cancer have primarily relied on genomic data from Caucasian populations. 4baseCare is bridging this critical genomics data gap in these regions, and I believe that it has the potential to make a big difference in the treatment approaches used in cancer.”
Commenting on the appointment, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “Lip-Bu Tan’s extensive experience as a venture capitalist will be incredibly valuable as we enter our next phase of growth. We believe that his role as an advisor will enable us to accelerate our efforts towards expanding to newer markets, building a sustainable company and impacting the lives of millions of people in need of cancer care.”
Over the next few months, 4baseCare will set up genomics laboratories in the Philippines, Nepal, and Dubai. Additionally, they will build genomics and digital health solutions, focusing on advanced data analytics, improved clinical insights, and data-driven treatment recommendations.